)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AdAlta
AdAlta (1AD) investor relations material
AdAlta Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary25 Oct, 2026
Executive summary
EW-001 advanced toward its first US FDA regulatory advice and first Australian manufacturing runs, supporting the “East to West” development strategy.
Clinical follow-up showed durable responses in China; Hainan regulators approved EW-001 for special access, while the program remains unapproved for general commercial launch.
Financial highlights
September-quarter net cash used in operating activities was A$0.584 million after a A$0.231 million R&D Tax Incentive refund; cash and cash equivalents ended at A$0.648 million.
Operating payments before the refund were ~A$0.81 million, down from A$1.84 million in the prior quarter, which included a non-recurring US$1 million payment to SHcell for trial costs and manufacturing materials.
An Advance Overseas Finding is expected to support R&D Tax Incentive inflows exceeding A$1 million in the December quarter.
Outlook and guidance
The pre-IND meeting is scheduled for 4 November 2026 AEST; FDA written minutes are generally issued two to four weeks after the meeting.
First Australian EW-001 manufacturing runs at CTPL remain expected in H2 2026; further R&D Tax Incentive inflows are expected in the December quarter.
The next formal assessments for two patients still on study are expected in Q1 2027; the second complete responder is among them.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AdAlta
- Losses increased as immunotherapy pipeline advanced and new capital was raised for key assets.1AD
H2 2026 - Lead CAR-T asset delivers strong results in mesothelioma, with scalable growth and partnering pipeline.1ADInvestor presentation
- Asian CAR-T innovation for solid tumors is rapidly commercialized in the West via a capital-efficient, de-risked model.1ADInvestor presentation
- Asian clinical assets are advanced for Western markets, with AD-214 ready for partnering.1ADStatus Update
- BZDS1901 CAR-T achieves rare, durable responses in mesothelioma, targeting a $4.2B+ market.1ADInvestor update
- Strong early CAR-T results in mesothelioma, but cash runway remains a key risk.1ADQ3 2026 TU
- Transformation to cellular immunotherapies advances, but losses and funding risks persist.1ADH2 2025
- Completed Phase I for AD-214, expanded pipeline, raised capital, but faces ongoing funding risks.1ADH2 2024
- Major CAR-T collaboration launched, loss narrowed, and $2.8M raised amid ongoing R&D focus.1ADH1 2026
Next AdAlta earnings date
H1 202718 Feb, 2027
AdAlta
Next AdAlta earnings date
H1 202718 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AdAlta Limited is an Australian biotechnology company focused on the discovery and development of novel protein-based therapeutics. The company utilizes its proprietary i-body technology platform to create next-generation biologic drugs targeting a range of diseases, including fibrosis and immune-related conditions. AdAlta Limited is headquartered in Melbourne, Australia, and its shares are listed on the ASX.